# US 2024/0189257 A1 · Compositions and methods for managing nephropathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189257 A1
- Document ID: US20240189257A1
- Status: Published application
- Kind: A1
- Application number: 18/282,672
- Filed: 2021-03-25
- Published: 2024-06-13
- Earliest claimed: 2021-03-25
- Assignees: Sami-Sabinsa Group Limited
- Applicants: Sami-Sabinsa Group Limited
- Inventors: Muhammed Majeed; Kalyanam Nagabhushanam; Sarang Bani; Anjali Pandey
- Web page: https://patentgrep.com/patent/US20240189257A1

## CPC

- A61K 31/12: Ketones
- A61K 31/7024: Esters of saccharides
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/37: Coumarins, e.g. psoralen
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61K 36/185: Magnoliopsida (dicotyledons)
- A61K 36/47: Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
- A61K 36/48: Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of nephropathy in mammals. The composition further comprises β-glucogallin and total mucic acid gallates, C-glucosides and tannins isolated from Pterocarpus marsupium. The invention also discloses the potential of the composition comprising β-glucogallin and total mucic acid gallates from Emblica officinalis, C-glucosides and tannins isolated from Pterocarpus marsupium in the therapeutic management of nephropathy.

## Claims

### Claim 1

A method for the therapeutic management of nephropathy in mammals, said method comprising step of administering a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids to mammals in need of such therapeutic management.

### Claim 2 (depends on 1)

The method as in claim 1, wherein the composition further comprises at least 10% w/w 1-O-galloyl-β-D-glucose (R-glucogallin) and at least 10% w/w total mucic acid gallates and ellagic acid, isolated from Emblica officinalis.

### Claim 3 (depends on 2)

The method as in claim 2, wherein the mucic acid gallates are selected from the group consisting of mucic acid 1,4-lactone 5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate and mucic acid 1-methyl ester 2-O-gallate.

### Claim 4 (depends on 1)

The method as in claim 1, wherein the composition further comprises of Pterocarpus marsupium extract standardized to contain tannins and C-glycosides containing not less than 0.5% w/w Pterocarposide, not less than 0.5% w/w Sabioside.

### Claim 5 (depends on 1)

The method as in claim 1, wherein nephropathy is induced by conditions selected from the group consisting of hyperglycemia, hypercholesterolemia, elevated blood pressure and renal hypertension, drugs, autoimmune diseases, oxidative stress and inflammation.

### Claim 6 (depends on 1)

The method as in claim 1, wherein the therapeutic effect is brough about by improving renal insufficiency, decreasing renal hypertension, reducing diabetic complications, decreasing inflammation and reducing the circulating levels of kidney markers in blood.

### Claim 7 (depends on 1)

The method as in claim 1, where in the mammal is human.

### Claim 8

A method for the maintaining normal kidney function in mammals, said method comprising step of administering a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids to mammals in need of such effect.

### Claim 9 (depends on 8)

The method as in claim 8, wherein the composition further comprises at least 10% w/w 1-O-galloyl-β-D-glucose (β-glucogallin) and at least 10% w/w total mucic acid gallates and ellagic acid, isolated from Emblica officinalis.

### Claim 10 (depends on 9)

The method as in claim 9, wherein the mucic acid gallates are selected from the group consisting of mucic acid 1,4-lactone 5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate and mucic acid 1-methyl ester 2-O-gallate.

### Claim 11 (depends on 8)

The method as in claim 8, wherein the composition further comprises of Pterocarpus marsupium extract standardized to contain tannis and C-glycosides containing not less than 0.5% w/w Pterocarposide, not less than 0.5% w/w Sabioside.

### Claim 12 (depends on 8)

The method as in claim 8, wherein the composition maintains normal kidney function in conditions selected from the group consisting of hyperglycemia, hypercholesterolemia, elevated blood pressure and renal hypertension, drugs, autoimmune diseases, oxidative stress and inflammation.

### Claim 13 (depends on 8)

The method as in claim 8, wherein the therapeutic effect is brough about by improving renal insufficiency, decreasing renal hypertension, reducing diabetic complications, decreasing inflammation and reducing the circulating levels of kidney markers in blood.

### Claim 14

A method for the therapeutic management of nephropathy in mammals, said method comprising step of administering a composition comprising at least 10% w/w 1-O-galloyl-β-D-glucose (β-glucogallin) and at least 10% w/w total mucic acid gallates and ellagic acid, isolated from Emblica officinalis and Pterocarpus marsupium extract standardized to contain tannins and C-glycosides containing not less than 0.5% w/w Pterocarposide, not less than 0.5% w/w Sabioside, to mammals in need of such therapeutic management.

### Claim 15 (depends on 14)

The method as in claim 14, wherein the mucic acid gallates are selected from the group consisting of mucic acid 1,4-lactone 5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate and mucic acid 1-methyl ester 2-O-gallate.

### Claim 16 (depends on 14)

The method as in claim 14, wherein nephropathy is induced by conditions selected from the group consisting of hyperglycemia, hypercholesterolemia, elevated blood pressure and renal hypertension, drugs, autoimmune diseases, oxidative stress and inflammation.

### Claim 17 (depends on 14)

The method as in claim 14, wherein the therapeutic effect is brough about by improving renal insufficiency, decreasing renal hypertension, reducing diabetic complications, decreasing inflammation and reducing the circulating levels of kidney markers in blood.

### Claim 18

A method for the maintaining normal kidney function in mammals, said method comprising step of administering a composition comprising at least 10% w/w 1-O-galloyl-β-D-glucose (β-glucogallin) and at least 10% w/w total mucic acid gallates and ellagic acid, isolated from Emblica officinalis and Pterocarpus marsupium extract standardized to contain tannis and C-glycosides containing not less than 0.5% w/w Pterocarposide, not less than 0.5% w/w Sabioside, to mammals in need of such effect.

### Claim 19 (depends on 18)

The method as in claim 18, wherein the mucic acid gallates are selected from the group consisting of mucic acid 1,4-lactone 5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-methyl ester 2-O-gallate and mucic acid 1-methyl ester 2-O-gallate.

### Claim 20 (depends on 18)

The method as in claim 18, wherein nephropathy is induced by conditions selected from the group consisting of hyperglycemia, hypercholesterolemia, elevated blood pressure and renal hypertension, drugs, autoimmune diseases, oxidative stress and inflammation.

### Claim 21 (depends on 18)

The method as in claim 18, wherein the therapeutic effect is brough about by improving renal insufficiency, decreasing renal hypertension, reducing diabetic complications, decreasing inflammation and reducing the circulating levels of kidney markers in blood.

### Claim 22 (depends on 18)

The method as in claim 18, wherein the mammal is human.
